Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Receivables (2016 - 2025)

Enanta Pharmaceuticals' Receivables history spans 14 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Receivables rose 10.04% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $8.5 million, up 10.04%, while the annual FY2025 figure was $6.9 million, 3.55% up from the prior year.
  • Receivables reached $8.5 million in Q4 2025 per ENTA's latest filing, up from $6.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $27.6 million in Q4 2021 to a low of $6.6 million in Q3 2024.
  • Average Receivables over 5 years is $14.4 million, with a median of $13.2 million recorded in 2023.
  • Peak YoY movement for Receivables: grew 15.93% in 2021, then crashed 63.81% in 2023.
  • A 5-year view of Receivables shows it stood at $27.6 million in 2021, then decreased by 18.31% to $22.6 million in 2022, then plummeted by 63.81% to $8.2 million in 2023, then fell by 5.57% to $7.7 million in 2024, then increased by 10.04% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Receivables are $8.5 million (Q4 2025), $6.9 million (Q3 2025), and $8.3 million (Q2 2025).